SCHEDULE: Janus Henderson Group Reports 9.7% Stake in Mirum Pharmaceuticals

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5,909,184 shares, representing 9.7% of Mirum Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Summary

• Janus Henderson Group Ltd. (JHG) has filed an amendment to its Schedule 13G, reporting beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock.
• This holding represents 9.7% of the class of securities.
• The filing indicates that the shares are held by various asset managers under JHG's umbrella, which exercise investment and/or voting discretion on behalf of their clients (Managed Portfolios).
• JHG disclaims beneficial ownership of dividends and proceeds from the sale of these securities, as these rights belong to the Managed Portfolios.
• The filing is an amendment to a previous filing, with the event date requiring this statement being June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership rather than a reflection of new company performance or strategy.

Positives

• Janus Henderson Group Ltd. is a significant institutional investor, and their reporting of a substantial stake (9.7%) can be seen as a positive signal of confidence in Mirum Pharmaceuticals.
• The clear disclosure of ownership provides transparency to the market regarding a major shareholder.

Negatives

• The filing does not contain any new financial performance data or strategic updates for Mirum Pharmaceuticals, making it difficult to assess the company's operational health from this document alone.
• The disclaimer of beneficial ownership for dividends and sale proceeds by JHG indicates that the ultimate economic interest lies with the underlying clients of the asset managers, not JHG itself.

Risks

• The filing does not explicitly mention any new risks for Mirum Pharmaceuticals.
• Potential future changes in Janus Henderson Group's investment strategy or client mandates could lead to shifts in their beneficial ownership, impacting Mirum's stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Mirum Pharmaceuticals' future performance. It is solely an update on beneficial ownership.

Management Comments

• Janus Henderson Group Ltd. disclaims any beneficial ownership associated with the rights to receive dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios.
• Kristin Mariani, Head of North America Compliance for Janus Henderson Group Ltd., certified the accuracy of the filing.

Industry Context

StockSavvy.ai notes that significant stakes reported by large asset managers like Janus Henderson Group are common in the pharmaceutical sector, reflecting active institutional investment in companies with growth potential. However, this filing is purely an ownership disclosure and does not comment on Mirum's specific market position or competitive landscape.

Stakeholder Impact

• Shareholders: The disclosure provides clarity on a significant institutional holder, which may influence investor perception and trading activity.
• Management of Mirum Pharmaceuticals: Awareness of Janus Henderson Group's substantial stake can inform strategic discussions and investor relations efforts.
• Regulators: The filing fulfills regulatory requirements for reporting significant beneficial ownership.

Next Steps

• Janus Henderson Group Ltd. will continue to hold or manage the reported securities on behalf of its clients.
• Future amendments to this Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

beneficial ownership, Schedule 13G, institutional investor, common stock, asset management, investment discretion, Mirum Pharmaceuticals